Trading
Data
Solutions
Insights
About
NowRx was founded in 2015 by Cary Breese. While Breese has not publicly discussed plans to participate in an IPO, NowRx hired Mark Marlow as it's first CFO in February 2022. Throughout his career, Marlow has helped guide two companies through successful IPOs. These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
NowRx is a telehealth platform that functions as a digital pharmacy, offering same-day delivery on prescriptions and other medical services. While the company has received funding from traditional VC firms, NowRx has shifted towards a crowdfunding model in recent funding rounds. NowRx has raised $79 million, $20 million of which was raised in a fully crowdfunded round. The latest round increased the company's pre-money valuation to $275 million.
NowRx is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own NowRx pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
NowRx is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 10/7/2021 | Series C | $74.03MM raised | $XXX.XX | $XXX.XX |
| 7/15/2020 | Series B | $22.4MM raised | $XXX.XX | $XXX.XX |
| 10/16/2018 | Series A | $17.68MM raised | $XXX.XX | $XXX.XX |
